Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The vehicle gel developed by G&E Herbal Biotechnology is an inactive topical formulation used as the placebo control in clinical trials for SR-T100, a solamargine-based treatment for actinic keratosis. This vehicle is designed to be pharmacologically inert, containing the same gel base and excipients as the active product but lacking the steroidal alkaloid glycoside solamargine. In Phase III clinical evaluations for actinic keratosis, the vehicle gel demonstrated a complete clearance rate of approximately 17.14%, compared to 32.4% for the active SR-T100 gel. It is applied topically once daily under an occlusive dressing for a 16-week treatment period to provide a baseline for efficacy and safety comparisons.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vehicle gel (G&E Herbal Biotechnology).